Dutch biotech firm, VectorY, has raised $138m to advance its antibody technology in the treatment of neurodegenerative diseases, particularly ALS. By targeting the misfolded protein TDP-43 with antibodies, VectorY’s drug therapy could potentially tackle an aggressive form of ALS that has previously proved difficult to treat. The funding will be used to push the lead programme, VTX-002, into clinical trials which are hoped to begin in early 2025.
Wirral University Hospital Faces Major Cybersecurity Crisis
Wirral University Teaching Hospital NHS Foundation Trust has declared a “major incident” due to a significant cyberattack that led to a shutdown of electronic systems.
